Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Esophageal Neoplasms

Neoplasms, Adipose Tissue

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Stomach Cancer

Esophageal Cancer

Myosteatosis

Yannick Deswysen, MD

Nicolas Lanthier, PhD

The aim of this project is to study the presence of cancer-associated adipocytes in oesogastric cancers and their possible links with myosteatosis. This research project has a retrospective component, the aim of which is to analyse the body component based on imaging in patients with oesogastric neoplasia in order to determine the incidence of myosteatosis and to study the relationship with oncological and prognostic data. The second part of the project is prospective and will collect biological material (skeletal muscle, adipose tissue, tumour, blood) for histological, molecular and genomic analyses and will analyse muscle function in patients with oesogastric cancer. It will address the role of adipocytes in the tumour microenvironment of oesogastric cancer, focusing on their interactions with the observed muscle myosteatosis and prognosis. In the future, it will help to identify signalling pathways, targets and patients who could benefit from appropriate treatment.

Oesophageal and gastric cancer pose a significant challenge to caregivers, both in terms of the complexity of its presentation and its treatment. At diagnosis, patients often present with malnutrition associated with sarcopenia, which has a significant impact on morbidity and mortality. Although loss of muscle mass has received much attention in cancer, muscle quality, particularly the accumulation of fat in muscle named "myosteatosis", may be considered as a better predictor of a patient's physical condition and ability to recover from cancer treatments. Studying the tumor microenvironment is essential to understanding the mechanisms underlying disease progression. Cancer-associated adipocytes (CAA), a major component of this tumor microenvironment, provide an interface for dialogue with the tumor through the secretion of pro-inflammatory cytokines, metalloproteases and the release of free fatty acids. They have been described as capable of stimulating tumor progression, particularly in breast cancer. However, their presence in oesogastric cancer and possible links with myosteatosis have not been described.

Myosteatosis in Oeso-gastric Cancer: Clinical Impacts

Muscle fat infiltration measured by analysis of tissue density based on a CT scan in L3 with the help of body component analysis software

Determining the presence and impact of tumor-associated adipocytes

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Nervous System Diseases

Symptoms and General Pathology

Sarcopenia

Colorectal Neoplasms

Intestinal Neoplasms

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Atrophy

Muscular Atrophy

Neuromuscular Manifestations

Neurologic Manifestations

Pathological Conditions, Anatomical

Karen Craver

Grant R Williams

Jay W Carlson

Site Public Contact

Gregory A. Masters

Gregory A Masters

Marcus S. Noel

Tareq Al Baghdadi

Bryan A. Faller

Bryan A Faller

Thomas E. Lad

Suparna Mantha

Jay W. Carlson

Bryan Faller

Joshua Lukenbill

William P Fusselman

Deborah W Wilbur

Deborah W. Wilbur

Richard L Deming

Raed Al-Rajabi

Victor Lin

Mindie M. Kavanaugh

Tareq Al baghadadi

Kathleen J Yost

Kathleen J. Yost

Daniel Almquist

Bret Friday

Pamala A. Pawloski

Pamala A Pawloski

Grant R Williams, MD

This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

This is a prospective cohort study that examines the impact of myopenia on chemotherapy toxicity in overall survival (OS) in older adults with newly diagnosed metastatic colorectal cancer (CRC) receiving 5-Fluouracil (5FU)systemic chemotherapy. The study also explores the mediating influence of genetic variation in the association between myopenia and chemotherapy toxicity.

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study

Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.

Chemotoxicity will be measured after initiation of chemotherapy using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).

Participants will be followed for the duration of the study with each participant followed for at least one year after diagnosis, to determine vital status. Loss-to-follow-up will be minimized by asking participating sites to provide date of last contact every 3 months.

University of Alabama at Birmingham

Wake Forest University Health Sciences

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Myosteatosis in Oeso-gastric Cancer: Clinical Impacts	NCT06419244	Esophageal Canc... Gastric Cancer Myopenia Adipose Tissue ...	Myosteatosis	18 Years -	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Myosteatosis in Oeso-gastric Cancer: Clinical Impacts	NCT06419244	Esophageal Canc... Gastric Cancer Myopenia Adipose Tissue ...	Myosteatosis	18 Years -	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer	NCT03998202	Colorectal Canc... Sarcopenia		60 Years -	Wake Forest University Health Sciences

Spots Global Cancer Trial Database for myopenia

Every month we try and update this database with for myopenia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for myopenia

Every month we try and update this database with for myopenia cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for myopenia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.